SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example
14 references·0 citing·45 second hop
A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example (2009)A Comparison of Cost Effectiveness Using …Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis (2009)Cost effectiveness of COX 2 s…Information on Cost-Effectiveness: An Essential Product of a National Comparative Effectiveness Program (2008)Information on Cost-Effective…External validity: the neglected dimension in evidence ranking (2006)External validity: the neglec…Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…The quality of published health economic analyses in digestive diseases: A systematic review and quantitative appraisal (2004)The quality of published heal…National Institute for Clinical Excellence and its value judgments (2004)National Institute for Clinic…Generalisability in economic evaluation studies in healthcare: a review and case studies (2004)Generalisability in economic …The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis (2003)The Cost-Effectiveness of Cyc…The Cost-Effectiveness of Acetaminophen, NSAIDs, and Selective COX-2 Inhibitors in the Treatment of Symptomatic Knee Osteoarthritis (2003)The Cost-Effectiveness of Ace…The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis (2003)The cost effectiveness of rof…A rational framework for decision making by the National Institute For Clinical Excellence (NICE) (2002)A rational framework for deci…Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses (2001)Quantifying stochastic uncert…Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland (2001)Economic Evaluation of Celeco…Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Guidelines for authors and pe…Methods for the economic evaluation of health care programmes (1987)Quality of life and pharmacoeconomics in clinical trials (1996)Inductive Teaching and Learning Methods: Definitions, Comparisons, and Research Bases (2006)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations (2022)Responsiveness of generic health-related quality of life measures in stroke (2005)Cost-Effectiveness in Health and Medicine (1996)Methods for Meta-Analysis in Medical Research (2000)Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies (2005)Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias (2009)The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought (2016)Markov Models in Medical Decision Making (1993)Variation in Patient Utilities for Outcomes of the Management of Chronic Stable Angina (1995)Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team (1995)Trends in Cost Effectiveness Analyses in Orthopaedic Surgery (2007)Trends in the non‐steroidal anti‐inflammatory drug market in six Central–Eastern European countries based on retail information (2009)Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities (2015)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)EuroQol: the current state of play (1996)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)Delivering affordable cancer care in high-income countries (2011)An Introduction to Markov Modelling for Economic Evaluation (1998)The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)Expected Value of Sample Information Calculations in Medical Decision Modeling (2004)Bayesian Methods for Evidence Synthesis in Cost-Effectiveness Analysis (2006)Whither trial‐based economic evaluation for health care decision making? (2006)Costs, effects and C/E‐ratios alongside a clinical trial (1994)Recommendations for Reporting Cost-effectiveness Analyses (1996)Net Health Benefits (1998)Gaussian Process Modeling in Conjunction with Individual Patient Simulation Modeling: A Case Study Describing the Calculation of Cost-Effectiveness Ratios for the Treatment of Established Osteoporosis (2004)The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report (2009)Cost-Effectiveness Analysis of Collaborative Care Management of Major Depression among Low-Income, Predominantly Hispanics with Diabetes (2011)Stability of Time-tradeoff Utilities in Survivors of Myocardial Infarction (1993)Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine (1994)10 Economics of osteoarthritis: a global perspective (1997)Moral hazard in insurance, value-based cost sharing, and the benefits of blissful ignorance (2008)The Journal's Policy on Cost-Effectiveness Analyses (1994)Growth and Quality of the Cost–Utility Literature, 1976–2001 (2005)Saying No Isn't NICE — The Travails of Britain's National Institute for Health and Clinical Excellence (2008)The Obama Administration's Options for Health Care Cost Control: Hope Versus Reality (2009)Healthcare Rationing by Proxy (2010)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 1996Guidelines for authors and peer reviewers of economic submissions to the BMJ1,821 cited
  • 2004National Institute for Clinical Excellence and its value judgments767 cited
  • 2002A rational framework for decision making by the National Institute For Clinical Excellence (NICE)455 cited
  • 2004Generalisability in economic evaluation studies in healthcare: a review and case studies441 cited
  • 2003The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis121 cited
  • 2003The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis114 cited
  • 2009Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis112 cited
  • 2001Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses112 cited
  • 2008Information on Cost-Effectiveness: An Essential Product of a National Comparative Effectiveness Program108 cited
  • 2004The quality of published health economic analyses in digestive diseases: A systematic review and quantitative appraisal95 cited
  • 2003The Cost-Effectiveness of Acetaminophen, NSAIDs, and Selective COX-2 Inhibitors in the Treatment of Symptomatic Knee Osteoarthritis63 cited
  • 2001Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

61 cited
  • 2006External validity: the neglected dimension in evidence ranking57 cited
  • Cited by

    No citing works inside the corpus for this window.